Status:
COMPLETED
To Evaluate the Efficacy of Z-338 in Subjects With Functional Dyspepsia
Lead Sponsor:
Zeria Pharmaceutical
Conditions:
Functional Dyspepsia
Eligibility:
All Genders
20-79 years
Phase:
PHASE2
Brief Summary
To Evaluate the efficacy of Z-338 in subjects with Functional Dyspepsia, focusing on the assessment of subjective symptoms in order to further determine the optimal dosage and efficacy parameters for ...
Eligibility Criteria
Inclusion
- Postprandial fullness, upper abdominal bloating and/or early satiety should be at least moderate for 2 days or more at the 7 days at Visit 1
- upper abdominal pain, upper abdominal discomfort, postprandial fullness, upper abdominal bloating, early satiety, nausea, vomit and belching should be at least moderate for at least 2 symptoms for 2 days or more at the 7 days at Visit 1
Exclusion
- subjects taht heartburn should be the most bothersome symptom
- Subjects presenting with primary complaints relieved by stool movements (IBS)
- Subjects with diabetes by treatment
- Subjects taht heartburn should be more than moderate
Key Trial Info
Start Date :
April 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
440 Patients enrolled
Trial Details
Trial ID
NCT00333372
Start Date
April 1 2006
Last Update
January 14 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tohoku University
Sendai, Japan